Specialized protein LNP encapsulation services for enzymes, recombinant proteins, antibody fragments, protein antigens, cytokines, growth factors, fluorescent proteins, and protein complexes.
Protein delivery is one of the most demanding applications for lipid nanoparticles because proteins are structurally complex, amphoteric, conformation-sensitive, and often vulnerable to interfacial stress, pH shift, organic solvent exposure, aggregation, and surface adsorption. Unlike nucleic acids, proteins do not follow a single charge-driven encapsulation model. Their molecular weight, isoelectric point, hydrophobic patches, glycosylation status, oligomeric state, disulfide structure, and buffer history can all influence loading efficiency, particle size, payload leakage, and retained biological activity. BOC Sciences provides protein LNP encapsulation services to help pharmaceutical and biotechnology researchers convert fragile protein payloads into stable, well-characterized LNP systems for intracellular delivery research, antigen presentation studies, enzyme delivery, protein replacement exploration, and functional in vitro evaluation. Our work integrates payload assessment, lipid composition design, microfluidic encapsulation, free protein removal, loading confirmation, particle characterization, and activity-aware formulation optimization.
Different protein payloads require different encapsulation logic. A compact enzyme, a charged cytokine, an antibody fragment, and a large protein complex may show completely different responses to lipid composition, aqueous phase conditions, mixing rate, and purification strategy. BOC Sciences provides payload-specific LNP encapsulation services for proteins with diverse structures, functions, and formulation sensitivities, helping research teams obtain reproducible LNP samples with clear analytical data and practical formulation interpretation.
Enzymes often require encapsulation conditions that protect tertiary structure and catalytic activity while reducing exposure to harsh interfaces. We develop enzyme-loaded LNPs for intracellular enzyme delivery research, activity restoration studies, and cell-based functional screening.
Recombinant proteins may vary widely in molecular size, charge distribution, folding stability, and surface hydrophobicity. We support LNP encapsulation for model proteins, therapeutic protein candidates, engineered proteins, and fusion proteins used in discovery-stage formulation research.
Antibody fragments, single-domain antibodies, and binding proteins may be sensitive to surface adsorption, local charge imbalance, and loss of binding conformation. We design LNP encapsulation workflows that focus on protein retention, particle quality, and preservation of binding-related structural features.
Protein antigens often require formulation conditions that preserve epitope presentation while improving particle association and sample uniformity. BOC Sciences supports protein antigen LNP encapsulation for antigen delivery research, immune-cell interaction studies, and comparative formulation screening.
Cytokines and growth factors are frequently low-dose, highly active proteins that may lose function through adsorption, oxidation, or aggregation. We help researchers formulate cytokine- and growth-factor-loaded LNPs with attention to low-input compatibility and retained biological relevance.
Fluorescent proteins and reporter proteins are useful for tracking intracellular delivery, uptake, and release behavior. We develop reporter protein LNPs for imaging-based evaluation, uptake comparison, formulation screening, and delivery mechanism studies.
Protein complexes and ribonucleoprotein assemblies require formulation conditions that preserve multi-component association while limiting particle heterogeneity. We support feasibility studies for protein complexes, enzyme assemblies, and CRISPR-related RNP systems.
When protein behavior is uncertain, a single formulation condition rarely provides enough information. We design multi-condition screens to identify lipid compositions and process windows that improve protein loading, particle uniformity, and retained function.
Protein LNP encapsulation requires coordinated control of formulation method, protein-lipid interaction, protein conformational stability, post-encapsulation processing, and analytical confirmation. BOC Sciences supports multiple encapsulation, stabilization, purification, and characterization technologies to help researchers develop protein-loaded lipid nanoparticles with improved loading performance, controlled particle attributes, and retained biological relevance.
Move beyond trial-and-error protein loading with formulation strategies that connect protein structure, lipid composition, encapsulation efficiency, particle quality, and retained activity.
BOC Sciences supports customized protein LNP encapsulation systems according to both functional application and protein molecular size. Because protein payloads differ greatly in molecular weight, charge distribution, folding stability, oligomeric state, and biological function, each LNP system requires a tailored formulation strategy. Our team helps researchers design protein-loaded LNPs for intracellular delivery, antigen presentation, enzyme delivery, targeted uptake, functional protein replacement research, and comparative formulation studies, while also considering the specific encapsulation challenges associated with small, medium, large, and complex protein payloads.
| Protein LNP Encapsulation System Type | Supported Protein Payloads, Functional Uses & Encapsulation Considerations | Request Information |
|---|---|---|
| Intracellular Protein Delivery LNP Encapsulation | Designed for proteins that need to reach the cytosol or intracellular compartments for functional evaluation. Supported payloads include enzymes, reporter proteins, engineered proteins, transcription-related proteins, and protein complexes. Formulation development focuses on protein protection during encapsulation, controlled particle size, reduced free protein signal, and sample suitability for in vitro uptake, localization, and functional assays. | Inquiry |
| Protein Antigen LNP Encapsulation | Suitable for recombinant protein antigens, peptide-protein conjugates, antigenic domains, and multimeric antigen constructs used in antigen presentation and immune-cell interaction research. We optimize encapsulation conditions to preserve epitope-related structure, reduce aggregation, improve particle uniformity, and generate characterized LNP samples for comparative cell-based evaluation. | Inquiry |
| Enzyme LNP Encapsulation | Supports hydrolases, oxidoreductases, nucleases, metabolic enzymes, lysosomal enzymes, and other functional proteins requiring retained catalytic activity after encapsulation. Development emphasizes mild formulation conditions, activity-aware buffer selection, aggregation control, free enzyme removal, and optional activity retention analysis to identify LNP candidates suitable for enzyme delivery research. | Inquiry |
| Targeted or Surface-Modified Protein LNP Encapsulation | Designed for projects requiring enhanced cellular interaction, receptor-oriented uptake, or comparative delivery to selected cell models. Supported modifications may involve peptide ligands, antibody fragments, small-molecule motifs, PEG-lipid anchors, or other surface-functional components. The formulation scope includes protein encapsulation, surface engineering feasibility, particle attribute confirmation, and target-interaction-oriented sample preparation. | Inquiry |
| Small Protein LNP Encapsulation (<25 kDa) | Suitable for small cytokines, growth factors, peptide-like proteins, compact binding domains, and small reporter proteins. These payloads may diffuse or leak more readily after formulation, so development focuses on improving lipid-protein association, reducing free protein content, optimizing retention after dilution, and minimizing sample loss during purification and buffer exchange. | Inquiry |
| Medium Protein LNP Encapsulation (25-80 kDa) | Applicable to many recombinant proteins, enzymes, fluorescent proteins, single-chain binding proteins, and engineered functional proteins. This size range often provides a practical balance between encapsulation feasibility and structural sensitivity. We screen lipid-to-protein ratio, formulation pH, buffer composition, and microfluidic conditions to optimize loading, particle uniformity, and retained functional signal. | Inquiry |
| Large Protein LNP Encapsulation (80-200 kDa) | Supports large enzymes, antibody fragments, Fc-fusion proteins, multivalent binding proteins, and structurally complex recombinant proteins. Large proteins may increase viscosity, particle heterogeneity, and aggregation risk during LNP formation. Our formulation strategy emphasizes gentle mixing, controlled protein concentration, lipid matrix optimization, and post-encapsulation stability evaluation. | Inquiry |
| Protein Complex LNP Encapsulation (>200 kDa) | Designed for multimeric proteins, enzyme complexes, assembled protein structures, protein-nucleic acid complexes, and other high-molecular-weight payloads. These systems often require feasibility-driven formulation because complex dissociation, broad particle distribution, or surface adsorption may occur. We evaluate component ratio, buffer compatibility, mixing stress, particle size, loading behavior, and complex integrity to identify practical encapsulation conditions. | Inquiry |
Protein LNP projects often fail when loading efficiency, protein activity, particle quality, and free protein removal are treated as separate problems. We address them as interconnected formulation variables.
✔ Low Protein Loading Efficiency
Protein may remain in the aqueous phase when lipid composition, pH, ionic strength, or lipid-to-protein ratio is not matched to protein charge and surface properties. We screen formulation variables to improve loading while monitoring particle quality and protein recovery.
✔ Protein Aggregation During LNP Formation
Aggregation can occur during rapid solvent dilution, pH transition, concentration steps, or contact with hydrophobic interfaces. We adjust buffer composition, mixing conditions, PEG-lipid content, and protein input concentration to reduce aggregation risk.
✔ Broad PDI and Poor Batch Reproducibility
Protein-lipid association can alter nanoparticle nucleation and growth, resulting in variable particle size distribution. We optimize flow rate ratio, total flow rate, lipid concentration, and aqueous-to-organic phase conditions to improve reproducibility.
✔ Loss of Protein Activity or Binding
Enzymes, antibody fragments, and growth factors may lose function after exposure to unfavorable pH, interfaces, or purification stress. We use activity-aware formulation design and optional functional readouts to identify conditions that better preserve protein performance.
✔ Free or Surface-Adsorbed Protein Interference
Residual free protein or externally adsorbed protein can distort uptake, localization, or functional assays. We combine purification with nanoparticle drug loading analysis strategies to differentiate total, free, and particle-associated protein.
✔ Payload Leakage After Dilution or Storage
Some proteins show acceptable initial loading but poor retention after buffer exchange, dilution, or incubation in assay media. We evaluate lipid matrix composition, PEG-lipid level, buffer conditions, and retention behavior to improve formulation robustness.
BOC Sciences provides practical experience in protein LNP formulation, microfluidic encapsulation, free protein analysis, loading optimization, and particle characterization to help researchers develop more stable and interpretable protein-loaded LNP systems.
We review protein molecular weight, pI, buffer composition, concentration, aggregation tendency, functional sensitivity, and target particle attributes to define a realistic encapsulation strategy.
Lipid molar ratios, lipid-to-protein ratio, charged lipid content, aqueous phase pH, ionic strength, total flow rate, and flow rate ratio are screened to identify promising formulation windows.
Candidate LNPs are prepared under controlled mixing conditions, followed by residual solvent reduction, free protein removal, and exchange into a protein- and particle-compatible buffer.
We report protein loading, particle size, PDI, zeta potential, protein recovery, free protein assessment, and key formulation observations to support the next research decision.
Challenge: A research team working with a 58 kDa cytosolic enzyme wanted LNP samples for intracellular delivery evaluation. Their initial formulation produced particles around 150-220 nm with PDI frequently above 0.30. Although total protein recovery appeared acceptable, catalytic activity after encapsulation dropped below 35% of the starting material, making the sample unsuitable for functional in vitro comparison.
Diagnosis: The original condition used a protein buffer with relatively high ionic strength and a fast solvent dilution step. This combination weakened controlled lipid-protein association and increased interfacial stress during particle formation. A post-formulation concentration step further increased aggregation, especially in samples with low PEG-lipid stabilization.
Solution: BOC Sciences designed a stepwise screen covering two aqueous buffer systems, three lipid-to-protein ratios, two PEG-lipid levels, and four microfluidic flow conditions. We first exchanged the protein into a milder buffer compatible with enzyme activity, then reduced protein input concentration during the mixing step to limit local aggregation. A moderate PEG-lipid increase improved colloidal stability, while an adjusted flow rate ratio narrowed particle size distribution. Candidate LNPs were purified using a gentler buffer exchange workflow and evaluated by DLS, zeta potential, protein loading, free protein content, and enzyme activity assay.
Result: The optimized condition produced enzyme-loaded LNPs with an average size of 82-110 nm, PDI below 0.20 across three preparation runs, and protein loading above 70% based on total/free protein comparison. Retained enzyme activity increased to approximately 72-78% of the starting activity, giving the client a more reliable sample set for intracellular delivery studies.
Challenge: A biotechnology client developing a protein antigen LNP observed a strong free-protein signal after purification. Initial batches showed apparent loading below 45%, particle size drift above 180 nm after 24-hour storage, and inconsistent uptake readouts in dendritic-cell-like models.
Diagnosis: The protein antigen had a pI close to the formulation pH, reducing useful electrostatic association during LNP self-assembly. Increasing total lipid concentration improved apparent loading slightly but caused broader particle distribution, suggesting that excess lipid promoted particle fusion rather than true protein entrapment.
Solution: Our team evaluated formulation pH values on both sides of the protein pI, compared neutral and mildly charged helper lipid designs, and screened lipid-to-protein ratios from 8:1 to 24:1. We also compared two purification methods to determine whether free antigen was being retained because of weak particle association or insufficient separation. Loading analysis was performed before and after particle disruption, while DLS and zeta potential data were used to reject conditions with aggregation risk. A final formulation candidate was selected based on lower free protein signal, narrower PDI, and better short-term retention after dilution into assay medium.
Result: The selected formulation achieved protein loading of 68-74%, particle size around 90-120 nm, and PDI below 0.22 after buffer exchange. Free protein signal decreased by more than 60% compared with the starting formulation, and the client obtained a cleaner antigen LNP sample for comparative cell-based uptake and response studies.
Flexible Service ScopeWe support projects ranging from rapid feasibility testing and single-payload encapsulation to multi-condition formulation screening, targeted protein LNP design, protein complex encapsulation, and broader LNP-based protein delivery development.
Protein-Specific Formulation ExpertiseOur formulation strategy is built around the actual properties of each protein payload, including molecular weight, pI, charge distribution, folding sensitivity, aggregation tendency, oligomeric state, and functional activity requirements.
Integrated Encapsulation and Characterization CapabilityWe connect protein loading analysis with particle size, PDI, zeta potential, free protein assessment, protein recovery, and activity-related readouts, helping clients understand both encapsulation performance and formulation quality.
Microfluidic Process Optimization ExperienceBy optimizing flow rate ratio, total flow rate, lipid-to-protein ratio, aqueous-to-organic phase conditions, and buffer transition, we help reduce batch variability, broad PDI, protein aggregation, and particle-size drift.
Activity-Aware Protein Protection StrategyFor enzymes, cytokines, growth factors, binding proteins, and protein antigens, we design mild formulation and post-processing conditions to reduce unfolding, precipitation, adsorption loss, and activity decline during LNP encapsulation.
Protein encapsulation in LNPs is challenging because proteins are structurally complex and highly sensitive to formulation stress. Unlike nucleic acids, proteins do not follow a single charge-driven encapsulation model. Their molecular weight, isoelectric point, hydrophobic patches, glycosylation, oligomeric state, disulfide structure, and buffer history can all influence loading efficiency, particle size, aggregation, leakage, and retained activity. During LNP formation, proteins may be exposed to pH shifts, organic solvent interfaces, rapid mixing, surface adsorption, and purification stress. Therefore, successful protein LNP development must evaluate not only how much protein is loaded, but also whether particle quality, free protein removal, and protein function remain suitable for downstream in vitro studies.
Protein loading efficiency can often be improved by matching the formulation strategy to the actual physicochemical properties of the protein payload. Key variables include aqueous phase pH relative to protein pI, lipid-to-protein ratio, ionizable or charged lipid content, PEG-lipid level, helper lipid composition, protein input concentration, ionic strength, and microfluidic mixing conditions. BOC Sciences typically applies multi-condition formulation screening rather than relying on a single preset formulation. By comparing total protein, free protein, particle-associated protein, particle size, PDI, zeta potential, and recovery, researchers can distinguish true encapsulation improvement from surface adsorption or unstable protein-lipid association.
Protein activity after LNP encapsulation should be assessed using payload-specific functional readouts. For enzymes, catalytic activity or substrate conversion can be compared before and after encapsulation. For antibody fragments, nanobodies, or binding proteins, binding-related signals may be evaluated. For fluorescent and reporter proteins, fluorescence retention, quenching, aggregation-related signal loss, and cell-based signal performance can be monitored. Total protein content alone is not sufficient because a protein may still be present but partially unfolded, aggregated, adsorbed, or functionally impaired. A more reliable evaluation combines encapsulation analysis, free protein assessment, particle size distribution, retention behavior, and activity- or binding-related measurements.
Yes. Residual free protein or surface-adsorbed protein can significantly distort the interpretation of LNP delivery experiments. In uptake, localization, antigen presentation, reporter protein, or functional restoration studies, a biological signal may come from unencapsulated protein rather than LNP-mediated intracellular delivery. Surface-associated protein may also cause non-specific cell binding, early leakage, particle-size drift, or misleading loading values. For this reason, protein LNP characterization should differentiate total protein, free protein, surface-associated protein, and particle-associated protein whenever possible. Purification, buffer exchange, disruption-based loading analysis, and retention testing are commonly used together to improve sample interpretability.
BOC Sciences supports customized protein LNP encapsulation services for enzymes, recombinant proteins, antibody fragments, nanobodies, protein antigens, cytokines, growth factors, fluorescent proteins, reporter proteins, protein complexes, and RNP-related systems. The service scope can include protein property review, lipid composition screening, microfluidic encapsulation, charge-assisted formulation design, free protein removal, buffer exchange, residual solvent reduction, particle size and PDI analysis, zeta potential measurement, protein loading assessment, and optional function-oriented evaluation. For scarce or high-value protein payloads, BOC Sciences can also design low-input screening workflows to identify formulation conditions that balance loading efficiency, particle uniformity, recovery, and retained biological relevance.
